Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)

Standard

Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). / Bockhorn, Maximilian; Uzunoglu, Faik G; Adham, Mustapha; Imrie, Clem; Milicevic, Miroslav; Sandberg, Aken A; Asbun, Horacio J; Bassi, Claudio; Büchler, Markus; Charnley, Richard M; Conlon, Kevin; Cruz, Laureano Fernandez; Dervenis, Christos; Fingerhutt, Abe; Friess, Helmut; Gouma, Dirk J; Hartwig, Werner; Lillemoe, Keith D; Montorsi, Marco; Neoptolemos, John P; Shrikhande, Shailesh V; Takaori, Kyoichi; Traverso, William; Vashist, Yogesh K; Vollmer, Charles; Yeo, Charles J; Izbicki, Jakob R; International Study Group of Pancreatic Surgery.

in: SURGERY, Jahrgang 155, Nr. 6, 01.06.2014, S. 977-988.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Bockhorn, M, Uzunoglu, FG, Adham, M, Imrie, C, Milicevic, M, Sandberg, AA, Asbun, HJ, Bassi, C, Büchler, M, Charnley, RM, Conlon, K, Cruz, LF, Dervenis, C, Fingerhutt, A, Friess, H, Gouma, DJ, Hartwig, W, Lillemoe, KD, Montorsi, M, Neoptolemos, JP, Shrikhande, SV, Takaori, K, Traverso, W, Vashist, YK, Vollmer, C, Yeo, CJ, Izbicki, JR & International Study Group of Pancreatic Surgery 2014, 'Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)', SURGERY, Jg. 155, Nr. 6, S. 977-988. https://doi.org/10.1016/j.surg.2014.02.001

APA

Bockhorn, M., Uzunoglu, F. G., Adham, M., Imrie, C., Milicevic, M., Sandberg, A. A., Asbun, H. J., Bassi, C., Büchler, M., Charnley, R. M., Conlon, K., Cruz, L. F., Dervenis, C., Fingerhutt, A., Friess, H., Gouma, D. J., Hartwig, W., Lillemoe, K. D., Montorsi, M., ... International Study Group of Pancreatic Surgery (2014). Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). SURGERY, 155(6), 977-988. https://doi.org/10.1016/j.surg.2014.02.001

Vancouver

Bibtex

@article{3767b1e8762044d48ef654e58e68dc72,
title = "Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)",
abstract = "BACKGROUND: This position statement was developed to expedite a consensus on definition and treatment for borderline resectable pancreatic ductal adenocarcinoma (BRPC) that would have worldwide acceptability.METHODS: An international panel of pancreatic surgeons from well-established, high-volume centers collaborated on a literature review and development of consensus on issues related to borderline resectable pancreatic cancer.RESULTS: The International Study Group of Pancreatic Surgery (ISGPS) supports the National Comprehensive Cancer Network criteria for the definition of BRPC. Current evidence supports operative exploration and resection in the case of involvement of the mesentericoportal venous axis; in addition, a new classification of extrahepatic mesentericoportal venous resections is proposed by the ISGPS. Suspicion of arterial involvement should lead to exploration to confirm the imaging-based findings. Formal arterial resections are not recommended; however, in exceptional circumstances, individual therapeutic approaches may be evaluated under experimental protocols. The ISGPS endorses the recommendations for specimen examination and the definition of an R1 resection (tumor within 1 mm from the margin) used by the British Royal College of Pathologists. Standard preoperative diagnostics for BRPC may include: (1) serum levels of CA19-9, because CA19-9 levels predict survival in large retrospective series; and also (2) the modified Glasgow Prognostic Score and the neutrophil/lymphocyte ratio because of the prognostic relevance of the systemic inflammatory response. Various regimens of neoadjuvant therapy are recommended only in the setting of prospective trials at high-volume centers.CONCLUSION: Current evidence justifies portomesenteric venous resection in patients with BRPC. Basic definitions were identified, that are currently lacking but that are needed to obtain further evidence and improvement for this important patient subgroup. A consensus for each topic is given.",
author = "Maximilian Bockhorn and Uzunoglu, {Faik G} and Mustapha Adham and Clem Imrie and Miroslav Milicevic and Sandberg, {Aken A} and Asbun, {Horacio J} and Claudio Bassi and Markus B{\"u}chler and Charnley, {Richard M} and Kevin Conlon and Cruz, {Laureano Fernandez} and Christos Dervenis and Abe Fingerhutt and Helmut Friess and Gouma, {Dirk J} and Werner Hartwig and Lillemoe, {Keith D} and Marco Montorsi and Neoptolemos, {John P} and Shrikhande, {Shailesh V} and Kyoichi Takaori and William Traverso and Vashist, {Yogesh K} and Charles Vollmer and Yeo, {Charles J} and Izbicki, {Jakob R} and {International Study Group on Pancreatic Surgery (ISGPS)}",
note = "Copyright {\textcopyright} 2014 Mosby, Inc. All rights reserved.",
year = "2014",
month = jun,
day = "1",
doi = "10.1016/j.surg.2014.02.001",
language = "English",
volume = "155",
pages = "977--988",
journal = "SURGERY",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "6",

}

RIS

TY - JOUR

T1 - Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)

AU - Bockhorn, Maximilian

AU - Uzunoglu, Faik G

AU - Adham, Mustapha

AU - Imrie, Clem

AU - Milicevic, Miroslav

AU - Sandberg, Aken A

AU - Asbun, Horacio J

AU - Bassi, Claudio

AU - Büchler, Markus

AU - Charnley, Richard M

AU - Conlon, Kevin

AU - Cruz, Laureano Fernandez

AU - Dervenis, Christos

AU - Fingerhutt, Abe

AU - Friess, Helmut

AU - Gouma, Dirk J

AU - Hartwig, Werner

AU - Lillemoe, Keith D

AU - Montorsi, Marco

AU - Neoptolemos, John P

AU - Shrikhande, Shailesh V

AU - Takaori, Kyoichi

AU - Traverso, William

AU - Vashist, Yogesh K

AU - Vollmer, Charles

AU - Yeo, Charles J

AU - Izbicki, Jakob R

AU - International Study Group on Pancreatic Surgery (ISGPS)

N1 - Copyright © 2014 Mosby, Inc. All rights reserved.

PY - 2014/6/1

Y1 - 2014/6/1

N2 - BACKGROUND: This position statement was developed to expedite a consensus on definition and treatment for borderline resectable pancreatic ductal adenocarcinoma (BRPC) that would have worldwide acceptability.METHODS: An international panel of pancreatic surgeons from well-established, high-volume centers collaborated on a literature review and development of consensus on issues related to borderline resectable pancreatic cancer.RESULTS: The International Study Group of Pancreatic Surgery (ISGPS) supports the National Comprehensive Cancer Network criteria for the definition of BRPC. Current evidence supports operative exploration and resection in the case of involvement of the mesentericoportal venous axis; in addition, a new classification of extrahepatic mesentericoportal venous resections is proposed by the ISGPS. Suspicion of arterial involvement should lead to exploration to confirm the imaging-based findings. Formal arterial resections are not recommended; however, in exceptional circumstances, individual therapeutic approaches may be evaluated under experimental protocols. The ISGPS endorses the recommendations for specimen examination and the definition of an R1 resection (tumor within 1 mm from the margin) used by the British Royal College of Pathologists. Standard preoperative diagnostics for BRPC may include: (1) serum levels of CA19-9, because CA19-9 levels predict survival in large retrospective series; and also (2) the modified Glasgow Prognostic Score and the neutrophil/lymphocyte ratio because of the prognostic relevance of the systemic inflammatory response. Various regimens of neoadjuvant therapy are recommended only in the setting of prospective trials at high-volume centers.CONCLUSION: Current evidence justifies portomesenteric venous resection in patients with BRPC. Basic definitions were identified, that are currently lacking but that are needed to obtain further evidence and improvement for this important patient subgroup. A consensus for each topic is given.

AB - BACKGROUND: This position statement was developed to expedite a consensus on definition and treatment for borderline resectable pancreatic ductal adenocarcinoma (BRPC) that would have worldwide acceptability.METHODS: An international panel of pancreatic surgeons from well-established, high-volume centers collaborated on a literature review and development of consensus on issues related to borderline resectable pancreatic cancer.RESULTS: The International Study Group of Pancreatic Surgery (ISGPS) supports the National Comprehensive Cancer Network criteria for the definition of BRPC. Current evidence supports operative exploration and resection in the case of involvement of the mesentericoportal venous axis; in addition, a new classification of extrahepatic mesentericoportal venous resections is proposed by the ISGPS. Suspicion of arterial involvement should lead to exploration to confirm the imaging-based findings. Formal arterial resections are not recommended; however, in exceptional circumstances, individual therapeutic approaches may be evaluated under experimental protocols. The ISGPS endorses the recommendations for specimen examination and the definition of an R1 resection (tumor within 1 mm from the margin) used by the British Royal College of Pathologists. Standard preoperative diagnostics for BRPC may include: (1) serum levels of CA19-9, because CA19-9 levels predict survival in large retrospective series; and also (2) the modified Glasgow Prognostic Score and the neutrophil/lymphocyte ratio because of the prognostic relevance of the systemic inflammatory response. Various regimens of neoadjuvant therapy are recommended only in the setting of prospective trials at high-volume centers.CONCLUSION: Current evidence justifies portomesenteric venous resection in patients with BRPC. Basic definitions were identified, that are currently lacking but that are needed to obtain further evidence and improvement for this important patient subgroup. A consensus for each topic is given.

U2 - 10.1016/j.surg.2014.02.001

DO - 10.1016/j.surg.2014.02.001

M3 - SCORING: Journal article

C2 - 24856119

VL - 155

SP - 977

EP - 988

JO - SURGERY

JF - SURGERY

SN - 0039-6060

IS - 6

ER -